Breaking News, Collaborations & Alliances

Stemline, LLS To Collaborate on BPDCN Treatment

Will develop treatment to target cancer stem cells

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Stemline Therapeutics, Inc. (STML) and The Leukemia & Lymphoma Society (LLS) will collaborate to accelerate the development of SL-401 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematological disorder with both leukemic and lymphomatous characteristics. LLS has committed more than $3 million to support this effort, as well as providing a comprehensive educational program to increase physician and patient awareness of BPDC...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters